Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Clinical Trial to Use Pharmacogenetics (PGx) to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

NCT00881114 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT00881114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00881114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Clinical Trial to Use Pharmacogenetics (PGx) to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
Lead sponsor
Georgetown University
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2009
Completion date
June 30, 2013
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer